Coagadex 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
N/0049 
Minor change in labelling or package leaflet not 
17/01/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
IAIN/0048 
B.II.b.2.c.1 - Change to importer, batch release 
21/12/2022 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
Annex II and 
PL 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
responsible for importation and/or batch release - 
Not including batch control/testing 
IAIN/0047 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
06/12/2022 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
IAIN/0045 
B.II.b.2.c.1 - Change to importer, batch release 
10/06/2022 
n/a 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IAIN/0044 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
02/05/2022 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
IA/0043 
B.II.z - Quality change - Finished product - Other 
18/03/2022 
n/a 
variation 
IB/0042 
B.III.2.b - Change to comply with Ph. Eur. or with a 
18/03/2022 
n/a 
national pharmacopoeia of a Member State - Change 
to comply with an update of the relevant monograph 
of the Ph. Eur. or national pharmacopoeia of a 
Member State 
IAIN/0041 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
10/12/2021 
n/a 
Page 2/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
PSUSA/10481
Periodic Safety Update EU Single assessment - 
30/09/2021 
n/a 
PRAC Recommendation - maintenance 
/202103 
human coagulation factor X 
IAIN/0040 
B.II.b.1.a - Replacement or addition of a 
07/07/2021 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IAIN/0038 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
24/03/2021 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
R/0031 
Renewal of the marketing authorisation. 
28/01/2021 
17/03/2021 
SmPC, Annex 
II, Labelling 
and PL 
IAIN/0037 
B.II.b.2.c.1 - Change to importer, batch release 
16/03/2021 
n/a 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IAIN/0036/G 
This was an application for a group of variations. 
13/01/2021 
17/03/2021 
Annex II and 
PL 
A.7 - Administrative change - Deletion of 
manufacturing sites 
Page 3/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A.5.a - Administrative change - Change in the name 
and/or address of a manufacturer/importer 
responsible for batch release 
IAIN/0035 
B.II.b.2.c.1 - Change to importer, batch release 
13/01/2021 
n/a 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IB/0034 
B.II.b.2.a - Change to importer, batch release 
11/12/2020 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
PSUSA/10481
Periodic Safety Update EU Single assessment - 
01/10/2020 
n/a 
PRAC Recommendation - maintenance 
/202003 
human coagulation factor X 
IB/0029 
B.II.b.3.z - Change in the manufacturing process of 
07/08/2020 
n/a 
the finished or intermediate product - Other variation 
IB/0027 
B.II.z - Quality change - Finished product - Other 
21/07/2020 
n/a 
variation 
IAIN/0032 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
06/07/2020 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
IAIN/0030 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
11/06/2020 
n/a 
Page 4/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
N/0024 
Minor change in labelling or package leaflet not 
26/03/2020 
n/a 
connected with the SPC (Art. 61.3 Notification) 
IAIN/0026 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
13/03/2020 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
IAIN/0025 
B.II.b.2.c.1 - Change to importer, batch release 
03/03/2020 
17/03/2021 
SmPC, Annex 
arrangements and quality control testing of the FP - 
II and PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
II/0023 
B.II.b.2.b - Change to importer, batch release 
16/01/2020 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place for a biol/immunol 
product and any of the test methods at the site is a 
biol/immunol method 
PSUSA/10481
Periodic Safety Update EU Single assessment - 
03/10/2019 
n/a 
PRAC Recommendation - maintenance 
/201903 
human coagulation factor X 
IAIN/0022/G 
This was an application for a group of variations. 
19/09/2019 
n/a 
Page 5/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
N/0020 
Minor change in labelling or package leaflet not 
30/07/2019 
17/03/2021 
PL 
connected with the SPC (Art. 61.3 Notification) 
IAIN/0019 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
19/07/2019 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
Page 6/10 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0021/G 
This was an application for a group of variations. 
18/07/2019 
n/a 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
Page 7/10 
 
 
 
 
 
 
 
 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
PSUSA/10481
Periodic Safety Update EU Single assessment - 
11/04/2019 
n/a 
PRAC Recommendation - maintenance 
/201809 
human coagulation factor X 
T/0014 
Transfer of Marketing Authorisation 
15/03/2019 
28/03/2019 
SmPC, 
Labelling and 
PL 
IAIN/0016 
B.IV.1.a.1 - Change of a measuring or administration 
20/03/2019 
n/a 
device - Addition or replacement of a device which is 
not an integrated part of the primary packaging - 
Device with CE marking 
N/0012 
Minor change in labelling or package leaflet not 
10/01/2019 
28/03/2019 
Labelling 
connected with the SPC (Art. 61.3 Notification) 
IA/0010 
A.7 - Administrative change - Deletion of 
26/10/2018 
n/a 
manufacturing sites 
PSUSA/10481
Periodic Safety Update EU Single assessment - 
04/10/2018 
n/a 
PRAC Recommendation - maintenance 
/201803 
human coagulation factor X 
II/0009 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
20/09/2018 
28/03/2019 
SmPC and PL 
new quality, preclinical, clinical or pharmacovigilance 
data 
Page 8/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
II/0007 
Update of section sections 4.1, 4.2, 4.8, 5.1 and 5.2 
26/07/2018 
27/08/2018 
SmPC and PL 
Please refer to the Scientific Discussion Coagadex 
EMEA/H/C/003855/II/0007. 
of the SmPC in order to include safety and efficacy 
data in children aged less than 12 years of age based 
on final results from the study Ten02, a phase III 
open-label multicentre study to confirm the safety, 
pharmacokinetics and efficacy of BPL’s high purity 
factor X in the prophylaxis of bleeding in factor X 
deficient children under the age of 12 years, 
provided in accordance with the agreed paediatric 
investigational plan. The Package Leaflet is updated 
accordingly. The RMP version 7.0 has also been 
submitted. 
C.I.6.a - Change(s) to therapeutic indication(s) - 
Addition of a new therapeutic indication or 
modification of an approved one 
IB/0006 
B.II.d.2.d - Change in test procedure for the finished 
23/05/2018 
n/a 
product - Other changes to a test procedure 
(including replacement or addition) 
PSUSA/10481
Periodic Safety Update EU Single assessment - 
12/04/2018 
n/a 
PRAC Recommendation - maintenance 
/201709 
human coagulation factor X 
IB/0005 
B.II.b.3.z - Change in the manufacturing process of 
14/12/2017 
n/a 
the finished or intermediate product - Other variation 
IB/0003 
B.II.b.3.z - Change in the manufacturing process of 
14/11/2017 
n/a 
the finished or intermediate product - Other variation 
PSUSA/10481
Periodic Safety Update EU Single assessment - 
28/09/2017 
n/a 
PRAC Recommendation - maintenance 
Page 9/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
/201703 
human coagulation factor X 
PSUSA/10481
Periodic Safety Update EU Single assessment - 
06/04/2017 
n/a 
PRAC Recommendation - maintenance 
/201609 
human coagulation factor X 
Page 10/10 
 
 
 
 
 
 
 
 
 
